HOME >> BIOLOGY >> NEWS
Herceptin plus chemotherapy significantly increases disease-free survival in breast cancer

Combining the molecularly targeted therapy Herceptin with chemotherapy in women with early stage breast cancer significantly improves disease-free survival for patients with a specific genetic mutation that results in very aggressive disease, a top UCLA researcher reported Thursday.

Dr. Dennis Slamon, whose laboratory and clinical research lead to the development of Herceptin, reported results of the Phase III study of more than 3,200 women Thursday at the 29th annual San Antonio Breast Cancer Symposium.

The three-armed study compared the standard therapy of Adriamycin and Carboplatin followed by Taxotere (ACT), an experimental regimen of Adriamycin and Carboplatin followed by Taxotere and one year of Herceptin (ACTH), and an experimental regimen of Taxotere and Carboplatin with one year of Herceptin (TCH).

The study tested Herceptin with and without Adriamycin, an anthracycline commonly used to treat breast cancer but one that, when paired with Herceptin, can cause permanent heart damage. Researchers wanted to determine whether they could provide a therapy as effective as ACTH without the resulting cardiac problems. The study, Slamon said, showed that the women who did not receive Adriamycin did just as well as those who did, and they experienced a five-fold decrease in significant heart toxicities compared to those who got Adriamycin. Also, some women in the ACTH arm developed leukemias, while none of the women on the non-Adriamycin arm did, Slamon said.

"This study demonstrates unequivocally that the best treatment for early stage HER-2 positive breast cancer is obtained with a non-anthracycline regimen, TCH, that avoids the significant cardiac damage found when Adriamycin is used with Herceptin," said Slamon, director of clinical/translational research at UCLAs Jonsson Cancer Center. "This trial should impact the way early stage breast cancer is treated, with TCH being considered the preferred option."

H
'"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
14-Dec-2006


Page: 1 2

Related biology news :

1. Gene profiling predicts resistance to breast cancer drug Herceptin
2. Herceptin plus chemotherapy improves disease-free survival in early breast cancer
3. Nanoparticles carry chemotherapy drug deeper into solid tumors
4. A faster way to recover from chemotherapy and marrow transplant
5. PET accurately identifies esophageal cancer patients positive responses to chemotherapy
6. Combining NSAIDs with chemotherapy, radiation may improve cancer treatment
7. FDG-PET imaging clearly predicts lung cancer patients response to chemotherapy
8. Gene analysis might explain ethnic differences in sensitivity to chemotherapy in lung cancer
9. Enhancing chemotherapys efficacy: New agent has synergistic effect with standard drugs
10. Massive gene screening points way to more effective chemotherapy
11. Researchers find the mechanism by which cells resist chemotherapy

Post Your Comments:
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
(Date:11/6/2014)... occur because of metastasis, yet progress in preventing ... , "It,s been particularly challenging to design drugs ... fellow in systems biology at Harvard Medical School. ... after they,ve already metastasized." , Gujral and colleagues ... help researchers better understand how metastasis begins. Their ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3
(Date:11/22/2014)... (PRWEB) November 21, 2014 RURO, ... solutions provider, has released Limfinity® version 5.1.4. , ... projects of Limfinity® than ever in RURO’s 8 ... and minority framework enhancement. Limfinity® version 5.1.4 is ... above and beyond bug fixes! , Limfinity® 5.1.4 ...
(Date:11/22/2014)... 2014  The element of surprise has been a ... strike without warning. Until now, epidemiologists had nothing to ... outbreak, resulting in suboptimal responses to both the H1N1 ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... because virus gene structural changes have been found that ...
(Date:11/21/2014)... 2014 The science of light and ... with more than 200 primary students in a traveling ... University of Otago Physics Department and funded by an ... members of the university’s OSA/SPIE Student Chapter visited six ... giving children from small, rural schools hands-on lessons in ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 ... (XNA, Chassis, Oligos, Enzymes, Cloning kits), Technology ... Application (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global ... major market drivers, threats, opportunities, and challenges. ... 46 figures spread through 185 pages and ...
Breaking Biology Technology:RURO Announces Limfinity® version 5.1.4 2Viruses' Advantage of Surprise is Lost 2Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4
Cached News: